Phase 1a/1b Study Results of Akeso's PD-1/CTLA-4 Bispecific Antibody Published in Cell Reports Medicine, Highlighting Promising Efficacy in Solid Tumors Refractory/Relapsed to Standard Therapy
HONG KONG, Oct. 19, 2023 /PRNewswire/ — Akeso (9926. HK) announced the publication of the phase 1a/1b first-in-human study (COMPASSION-01) evaluating cadonilimab (PD-1/CTLA-4 bispecific antibody) in patients with advanced solid tumors in Cell Reports Medicine, a sub-publication of Cell. Full article: https://www.cell.com/cell-reports-medicine/fulltext/S2666-3791(23)00419-6# The study findings revealed that cadonilimab reached a dose of 25 mg/kg every […]